Ferrer Internacional S.A.
Quick facts
Marketed products
- Furosemide-IR
- retapamulin 1% ointment
- torasemide-IR
- torasemide-PR · Cardiovascular
Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes. - Torasemide Prolonged Release
Phase 3 pipeline
- ozenoxacin 1% cream · Dermatology
Ozenoxacin is a quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.
Phase 2 pipeline
- arasertaconazole nitrate
- FNP-223 · Immunology
FNP-223 is a small molecule that targets the S1P1 receptor. - GF-001001-00 · Infectious Diseases
GF-001001-00 is a small molecule that targets the HCV NS5A protein.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Ferrer Internacional S.A.
What are Ferrer Internacional S.A.'s marketed drugs?
Top marketed products include Furosemide-IR, retapamulin 1% ointment, torasemide-IR, torasemide-PR, Torasemide Prolonged Release.
What is Ferrer Internacional S.A.'s pipeline?
Ferrer Internacional S.A. has 1 drugs in Phase 3, 3 in Phase 2, 1 in Phase 1. Late-stage candidates include ozenoxacin 1% cream.
Related
- Furosemide-IR
- retapamulin 1% ointment
- torasemide-IR
- torasemide-PR · Cardiovascular
- Torasemide Prolonged Release
- Sector hub: All tracked pharma companies